



# Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region

M. Chandran<sup>1</sup> · P. J. Mitchell<sup>2</sup> · T. Amphansap<sup>3</sup> · S. K. Bhadada<sup>4</sup> · M. Chadha<sup>5</sup> · D.-C. Chan<sup>6</sup> · Y.-S. Chung<sup>7</sup> · P. Ebeling<sup>8</sup> · N. Gilchrist<sup>9</sup> · A. Habib Khan<sup>10</sup> · P. Halbout<sup>11</sup> · F. L. Hew<sup>12</sup> · H.-P. T. Lan<sup>13</sup> · T. C. Lau<sup>14</sup> · J. K. Lee<sup>15</sup> · S. Lekamwasam<sup>16</sup> · G. Lyubomirsky<sup>17</sup> · L. B. Mercado-Asis<sup>18</sup> · A. Mithal<sup>19</sup> · T. V. Nguyen<sup>20</sup> · D. Pandey<sup>21</sup> · I. R. Reid<sup>22</sup> · A. Suzuki<sup>23</sup> · T. T. Chit<sup>24</sup> · K. L. Tiu<sup>25</sup> · T. Valleenukul<sup>26</sup> · C. K. Yung<sup>27</sup> · Y. L. Zhao<sup>28</sup> · on behalf of the Asia Pacific Consortium on Osteoporosis (APCO)

Received: 2 October 2020 / Accepted: 11 November 2020  
© The Author(s) 2021

## Abstract

**Summary** Guidelines for doctors managing osteoporosis in the Asia-Pacific region vary widely. We compared 18 guidelines for similarities and differences in five key areas. We then used a structured consensus process to develop clinical standards of care for the diagnosis and management of osteoporosis and for improving the quality of care.

**Purpose** Minimum clinical standards for assessment and management of osteoporosis are needed in the Asia-Pacific (AP) region to inform clinical practice guidelines (CPGs) and to improve osteoporosis care. We present the framework of these clinical standards and describe its development.

**Methods** We conducted a structured comparative analysis of existing CPGs in the AP region using a “5IQ” model (identification, investigation, information, intervention, integration, and quality). One-hundred data elements were extracted from each guideline. We then employed a four-round Delphi consensus process to structure the framework, identify key components of guidance, and develop clinical care standards.

**Results** Eighteen guidelines were included. The 5IQ analysis demonstrated marked heterogeneity, notably in guidance on risk factors, the use of biochemical markers, self-care information for patients, indications for osteoporosis treatment, use of fracture risk assessment tools, and protocols for monitoring treatment. There was minimal guidance on long-term management plans or on strategies and systems for clinical quality improvement. Twenty-nine APCO members participated in the Delphi process, resulting in consensus on 16 clinical standards, with levels of attainment defined for those on identification and investigation of fragility fractures, vertebral fracture assessment, and inclusion of quality metrics in guidelines.

**Conclusion** The 5IQ analysis confirmed previous anecdotal observations of marked heterogeneity of osteoporosis clinical guidelines in the AP region. The Framework provides practical, clear, and feasible recommendations for osteoporosis care and can be adapted for use in other such vastly diverse regions. Implementation of the standards is expected to significantly lessen the global burden of osteoporosis.

**Keywords** Asia-Pacific · Consensus · Guidelines · Osteoporosis · Standards of care

## Introduction

Osteoporotic hip fractures among people in the Asia-Pacific region are expected to increase dramatically due to population aging, urbanization, and associated sedentary lifestyles [1]. Of these factors, population aging represents the major challenge, with the population of East Asia and the Pacific reported to be aging more rapidly than any other region in history [2]. The number of people who are 60 years and over in the Asia-

---

✉ M. Chandran  
manju.chandran@singhealth.com.sg

Extended author information available on the last page of the article

Pacific region is predicted to triple between 2010 and 2050, reaching an estimated 1.3 billion by 2050 [3]. The old-age dependency ratio (OADR) is defined as the number of persons aged 65 years or over (assumed to be economically inactive) per 100 persons of working age (20 to 64 years). It provides an index of the economic dependency associated with aging populations and is expected to more than double in Eastern and South-Eastern Asia between 2019 and 2050, rising from 18 older persons per 100 workers in 2019 to 43 in 2050. It is predicted that Japan which was reported to have the highest OADR in the world in 2019 will remain in first position in 2050, followed closely by several other countries and regions in Eastern and South-Eastern Asia [4].

The Asia Pacific Consortium on Osteoporosis (APCO), a non-partisan and apolitical organization, is comprised of osteoporosis experts drawn from a diverse range of clinical settings, from low-, middle-, and high-income countries and regions in the Asia-Pacific that have populations ranging between 4.8 million and 1.4 billion people.

APCO aims to develop regionally relevant, pragmatic, and effective strategies for improving osteoporosis management and reducing rates of fragility fractures. Adoption of such strategies would lessen the burden of osteoporosis in this vast region that accounts for more than 60% of the world's population [5]. We have previously described APCO's *raison d'être*, conception and launch, vision, mission, and priority initiatives [6].

Launched in May 2019, APCO's first project was to develop clear and concise standards for the screening, diagnosis, and management of osteoporosis that are pan Asia-Pacific in their reach. This decision was based on anecdotal observations that existing guidelines for osteoporosis management within the Asia-Pacific region are heterogeneous and vary widely in scope and recommendations. Access to primary care services and bone mineral density (BMD) assessment varies across jurisdictions and regions, and little is known about adherence to current guidelines in day-to-day clinical practice. APCO therefore determined to (i) conduct a systematic, structured analysis of existing guidelines in the Asia-Pacific region, (ii) identify regionally relevant key guideline elements using a structured consensus process, and (iii) develop, through a structured consensus process, feasible regional clinical care standards that will both support clinical improvement initiatives and provide a framework for the development of new national clinical practice guidelines or the revision of existing ones.

This article describes the process by which, on a background of the existing guidelines in the Asia-Pacific region, APCO members developed and endorsed a new set of minimum standards of care that can be adapted and adopted across the region. We also highlight emerging themes in osteoporosis that have not yet been incorporated into any of the existing guidelines, but have enormous implications and potential to change the landscape of osteoporosis treatment.

## Methods

A framework of minimum clinical care standards (the Framework) was developed in two stages: (i) a detailed comparative analysis of osteoporosis clinical practice guidelines in the Asia-Pacific region, and (ii) a structured consensus process to draft the standards.

### Comparative analysis of osteoporosis guidelines in the Asia-Pacific region

Existing national or regional clinical practice guidelines and/or standards of care were identified through a survey among APCO members. A structured template was developed to facilitate standardized identification of guideline components. The template was based on the "5IQ" model (Table 1), modifications of which have been used to develop clinical standards for fracture liaison services (FLSs) in Japan [7], New Zealand [8], and in the UK [9].

For each guideline, we identified the format in which the recommendations/information were provided and extracted details of these parameters. One hundred data elements were extracted from each guideline (the template used for extracting data from clinical practice guidelines is provided in Appendix 1):

- Background information (8 elements).
- Case identification (34 elements). Checklists of risk factors were derived from a recent review examining case-finding strategies from a global perspective [10].
- Investigation (21 elements).
- Advice and education for patients (5 elements).
- Interventions (28 elements), including indications for treatment, treatments, recommendations for follow-up and duration of treatment, and recommendations for falls prevention. Given the complexity of indications, a coding system was created to allow quantitative comparison. Commentary on treatment/supplementation with calcium and/or vitamin D was also coded to compare the proportions of guidelines that recommended these options as active therapy, as distinct from adjunctive therapy alongside osteoporosis-specific treatments.
- Strategies for long-term management and integration of osteoporosis care into the health system (2 elements).
- Strategies to promote the quality of clinical care (2 elements).

Findings were analyzed separately for guidelines published between 2015 and 2020 ("newer guidelines") and those published before 2015 ("older guidelines").

**Table 1** The 5IQ model for analyzing the content of clinical practice guidelines

Component	Description
Identification	A statement of which individuals should be identified
Investigation	A description of the types of investigations that will be undertaken
Information	A description of the types of information that will be provided to the individual
Intervention	A description of pharmacological interventions and falls prevention
Integration	A statement on the need for integration between primary and secondary care
Quality	A description of professional development, audit, and peer-review activities

## Consensus process for developing the clinical care standards framework

A four-round Delphi process was adopted to develop standards of care for osteoporosis risk assessment, diagnosis, and management that are appropriate for the Asia Pacific region. The Delphi method has been widely used for establishing clinical consensus on other clinical conditions [11]. This structured approach ensures that the opinions of participants are equally considered, and it is particularly useful for geographically diverse groups like APCO. The Delphi process was conducted through online questionnaires.

### Round 1

APCO members were invited to determine which aspects of care required clinical standards to be developed, based on a list informed by the findings of the 5IQ comparative analysis. The questionnaire included 32 questions under three domains (Appendix 2):

- Domain 1. What are the notable findings from the 5IQ Comparative analysis of osteoporosis clinical guidelines from across the Asia Pacific region? Participants were referred to specific sections within the analysis report and invited to identify important findings.
- Domain 2: How should the Framework be structured? Participants were asked to indicate how the Framework should be structured, including whether levels of attainment should be included for clinical standards to serve as potential quality performance indicators.
- Domain 3. What clinical standards are required? For each of 21 key elements identified in the 5IQ analysis of Asia-Pacific clinical practice guidelines, participants were asked their opinion on the importance of its inclusion as a clinical standard (5-point scale from “extremely important” to “not at all important,” with optional free text comments). Consensus was defined as a ranking of “extremely important” or “very important” by at least 75% of respondents. Participants were also invited to make any general comments on development of the Framework.

### Round 2

Members were asked to express their agreement (or not) with the wording of 16 draft clinical standards, of which several included proposed wording on levels of attainment (5-point scale from “strongly agree” to “strongly disagree”). For each draft standard, members were also invited to propose alternative wording or make comments. Consensus was defined as a ranking of “strongly agree” or “agree” by at least 75% of respondents.

### Round 3

The wording of clinical standards and levels of attainment was amended, based on the results of Round 2. APCO members were invited to approve amendments (yes/no options). Consensus was defined as a “yes” response to a proposed rewording by at least 75% of respondents.

### Round 4

A fourth round was conducted after some of the standards and levels of attainment were again reworded for clarity and precision without changing their intent. The minor amendments to the wording of the standards, with commentary itemizing each change, were sent to the APCO members who had participated in one or more of the previous Delphi rounds. Members were instructed to reply to the Chairperson by a stipulated date if they had any objection to the rewording of the standards.

## Results

The analysis included 18 guidelines (Table 2) from the following regions: Australia [12], China (three guidelines) [13–15], Chinese Taipei [16], Hong Kong Special Administrative Region of the People’s Republic of China (SAR) [17], India (two guidelines) [18, 19], Indonesia [20], Japan [21], Malaysia [22], Myanmar [23], New Zealand [24], the Philippines [25], Singapore [26], South Korea [27], Thailand [28], and Vietnam [29]. Of these, 14 (78%) were published between 2015 and 2020. Two-thirds of the

**Table 2** Osteoporosis management clinical practice guidance documents included in the 5IQ analysis

Country or region	Organization(s)	Name of guideline
Australia	Osteoporosis Australia The Royal Australian College of General Practitioners	Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age [1]
China	Osteoporosis and Bone Mineral Disease Branch of Chinese Medical Association	Guidelines for the diagnosis and treatment of primary osteoporosis [2]
China	Osteoporosis Society of China Association of Gerontology and Geriatrics	2018 China guideline for the diagnosis and treatment of senile osteoporosis [3]
China	Osteoporosis Group, Orthopedic Branch, Chinese Medical Association	Guidelines for the diagnosis and treatment of osteoporotic fractures [4]
Hong Kong SAR	The Osteoporosis Society of Hong Kong	OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong [5]
Chinese Taipei	Taiwanese Osteoporosis Association	Consensus and guidelines for the prevention and treatment of adult osteoporosis in Taiwan [6]
India	Indian Menopause Society	Clinical practice guidelines on postmenopausal osteoporosis: An executive summary and recommendations [7]
India	Indian Society for Bone and Mineral Research	Indian Society for Bone and Mineral Research guidelines 2020 [8]
Indonesia	Indonesian Osteoporosis Association (Perhimpunan Osteoporosis Indonesia)	Summary of the Indonesian guidelines for diagnosis and management of osteoporosis [9]
Japan	Japan Osteoporosis Society The Japanese Society for Bone and Mineral Research Japan Osteoporosis Foundation	Japanese 2015 guidelines for the prevention and treatment of osteoporosis [10]
Malaysia	Malaysian Osteoporosis Society Academy of Medicine Ministry of Health Malaysia	Clinical guidance on management of osteoporosis [11]
Myanmar	Myanmar Society of Endocrinology and Metabolism	Myanmar clinical practice guidelines for osteoporosis [12]
New Zealand	Osteoporosis New Zealand	Guidance on the diagnosis and management of osteoporosis in New Zealand [13]
Philippines	Osteoporosis Society of Philippines Foundation Philippine Orthopedic Association	Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines [14]
Singapore	Agency for Care Effectiveness, Ministry of Health Singapore	Appropriate care guide: osteoporosis identification and management in primary care [15]
South Korea	Korean Society for Bone and Mineral Research	KSBMR Physician's Guide for Osteoporosis [16]
Thailand	Thai Osteoporosis Foundation	Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis [17]
Vietnam	Vietnam Rheumatology Association	Guidelines for the diagnosis and treatment of osteoporosis [18]

guidelines did not specify a date for planned revision. Six stated that an update within 3–5 years was planned.

Eleven of the guidelines were available in English. A professional medical translation agency was commissioned to translate four guidelines from Chinese, and the Vietnamese guideline was translated by an APCO member. Data extraction for the Japanese guidelines was undertaken by an APCO member and that for the Korean guideline was undertaken by a native speaker who was also an osteoporosis clinician.

## Identification

### Risk factors/indications for assessment and evaluation

Fifteen of the 18 guidelines cited risk factors separately for men and women, two guidelines for women only, and another did not state the sex to which cited risk factors applied.

The most commonly cited risk factors for osteoporosis (cited in at least half the guidelines) were excessive alcohol consumption (17 guidelines), a family history of osteoporosis and/or fractures (17 guidelines), smoking (17 guidelines), low body mass index (BMI)/weight (16 guidelines), height loss (13 guidelines), age over 70 years (13 guidelines), and early menopause (12 guidelines).

A range of other age thresholds for increased risk was also identified, with several citing one or more of the following: adults (four guidelines), postmenopausal women (three guidelines), 50 years and above (two guidelines), 60 years and above (one guideline), and 65 years and above in men (one guideline).

All 18 guidelines cited a history of fragility fracture as a risk factor for subsequent fracture. Thirteen of 18 guidelines specified the type of fragility fractures, most commonly spine, hip, proximal femur, wrist, forearm, distal radius, humerus, pelvis, and ribs. In the context of case identification, one

guideline from China mentioned the importance of FLSs to promote multidisciplinary joint diagnosis and treatment.

While all the guidelines identified glucocorticoid treatment as being associated with bone loss and/or increased fracture risk, the lists of other medicines associated with bone loss varied between guidelines. More than half of the guidelines also identified users of androgen deprivation therapy (11/18 guidelines), anticoagulants (9/18 guidelines), anticonvulsants (10/18 guidelines), and aromatase inhibitors (11/18 guidelines) as at-risk groups. Other medications that were identified included proton pump inhibitors, thiazolidinediones, and selective serotonin reuptake inhibitors.

The medical conditions most frequently cited as risk factors were rheumatoid arthritis, malabsorption, hyperthyroidism, and multiple myeloma. Diabetes was noted as a risk factor in 10 of 14 (71%) of the newer guidelines, compared with none of the older guidelines.

## Investigation

### Biochemical tests

The extent of commentary on assays for bone turnover markers and other biochemical parameters varied considerably between the guidelines. Some guidelines only briefly mentioned biochemical tests in the evaluation of osteoporosis, while others provided detailed guidance. Total procollagen type 1 N-terminal propeptide (P1NP) was the most frequently recommended bone turnover marker (16/18 guidelines). Other laboratory tests that were commonly recommended in the guidelines included calcium, alkaline phosphatase, 25-hydroxyvitamin D, creatinine, urinary N-telopeptide (uNTX), parathyroid hormone (PTH), and osteocalcin.

### Risk assessment tools

The FRAX® fracture risk assessment tool [30] was by far the most commonly recommended risk assessment tool (17/18 guidelines), followed by the Osteoporosis Self-Assessment Tool for Asians (OSTA) (11/18 guidelines) [31]. Some newer guidelines also recommended a range of other tools: the Garvan nomogram [32] (three guidelines), IOF Risk Check (“one-minute osteoporosis risk test”)[33] (three guidelines), the Khon Kaen Osteoporosis Study (KKOS) scoring system [34] (one guideline), the Male Osteoporosis Risk Estimation Score (MORES) [35] (1 guideline), QFracture algorithm [36, 37] (one guideline), and Simple Calculated Osteoporosis Risk Estimation (SCORE) [38] (one guideline).

### Vertebral fracture assessment

All 18 guidelines mentioned the use of radiography to identify vertebral fractures, with some directly recommending x-ray of

the thoracic and lumbar spine, some advising when it should be considered, and one simply noting that bone loss and healing fractures may be evident on radiographs. Dual-energy x-ray absorptiometry (DXA)-based vertebral fracture assessment (VFA) was mentioned in eight guidelines, with guidance ranging from just statements of its existence or simple advice to consider DXA for identifying fractures, to the inclusion of DXA-identified fractures in treatment indications.

### Falls risk assessment

Thirteen of 18 guidelines referred to the importance of falls risk assessment. The degree of detail varied widely with some amount of detail specified in the guidelines from Australia, China, Hong Kong SAR, Chinese Taipei, India, Malaysia, Japan, Thailand, and New Zealand. Some guidelines emphasized that falls risk assessment should be conducted routinely in all older adults (Australia), while others discussed falls risk assessment for patients known to be at risk of fragility fractures or with a history of fracture. One of the Chinese guidelines recommended that attention should be paid to the evaluation of fall-related risk factors in elderly patients with osteoporosis. Some guidelines recommended certain aspects of assessment, such as muscle strength and balance, while the Hong Kong SAR and one of the other Chinese guidelines provided comprehensive guidance on specific medical and environmental risk factors to consider when performing the assessment. Some mentioned strategies or structured tools for performing falls risk assessment (Thailand).

### Specialist assessment

Ten of 18 guidelines recommended specialist referral for assessment in certain clinical scenarios. Four recommended that any patient with fragility fractures or osteoporosis should be referred for specialist assessment or care. Other specified scenarios included fracture or persistent loss of BMD despite treatment, complex conditions, problems considered “difficult” or beyond the scope of primary care, secondary osteoporosis, severe or unusual presentation, when first-line treatments were contraindicated or not tolerated, when assessment for specialized treatments is needed (e.g., teriparatide or long-term estrogen therapy), and when bone densitometry is not available.

### Information

There was considerable variation in the extent to which the various guidelines recommended that specific information should be provided to patients.

## Calcium intake and exercise

All 18 guidelines recommended that information should be provided on calcium intake, and 17 recommended providing information on exercise.

## Sun exposure

Ten out of 18 guidelines (including one older guideline) recommended that patients should be provided with information on sun exposure to maintain healthy vitamin D levels.

## Fracture risk

Only seven out of 18 guidelines (all newer guidelines) recommended that patients should be given information about the link between osteoporosis and fracture risk.

## Intervention

### Indications for treatment

All 18 guidelines cited BMD T-score of  $\leq -2.5$  standard deviations (SD) as an indication for treatment. The reference database to be used to delineate T-scores was specified in only a minority of the guidelines. A broad range of other indications for treatment were cited in the various guidelines, with each guideline typically featuring three or four of a total of 14 indications identified.

Most guidelines cited hip and vertebral fractures as an indication for treatment. Fifteen of the 17 guidelines that included hip fracture as an indication for treatment, and all 17 guidelines that included vertebral fracture as an indication for treatment, stated that BMD testing was not required to initiate treatment. Of the 15 guidelines that included non-hip, non-vertebral fracture as an indication for treatment initiation, nine suggested that BMD testing was not necessary prior.

Thirteen guidelines mentioned or recommended treatment thresholds based on FRAX® probabilities. Six guidelines cited the threshold recommended by the US National Osteoporosis Foundation guidelines [39] (BMD T-Score in the osteopenic range, in combination with a FRAX® 10-year probability of  $\geq 3\%$  for hip fracture risk or  $\geq 20\%$  for major osteoporotic fracture risk). Of these, only two (the Malaysian guideline and one of the guidelines from China) explicitly recommended that this threshold should be adopted for their local target population. The Hong Kong SAR guideline stated that the US criteria were provided for clinical guidance only and that treatment decisions should consider individual patient factors. Other guidelines cited the US treatment threshold as an example or in commentary, without further interpretation.

Some guidelines provided guidance on the logistics and limitations of applying FRAX® to local populations. One of

the guidelines from China [15] stated that the current prediction results may underestimate fracture risk in the Chinese population. Several others recommended the use of population specific FRAX® algorithms (e.g., Hong Kong SAR, India, Singapore, Thailand, Vietnam).

Osteopenia in combination with other criteria (e.g., presence of risk factors, risk scores,  $\geq 10$  years post menopause) was included in several guidelines.

## Pharmacological treatment options

Less than one-third of guidelines classified treatment options as first line, second line, and third line. All guidelines recommended bisphosphonates (oral and intravenous) and raloxifene as treatment options for osteoporosis. Most guidelines also recommended denosumab, teriparatide, and hormone replacement therapy (HRT). Predictably, the recently introduced treatments, abaloparatide and romosozumab, were recommended in only two newer guidelines (India and Korea).

## Adjunctive treatments

Calcium and vitamin D were recommended as adjunctive therapies more often than as active treatments. That calcium was not a treatment option was explicitly stated in less than half of the guidelines.

## Adverse effects

The volume of commentary on potential adverse effects of osteoporosis treatments varied considerably between guidelines. Eleven of 18 guidelines provided information on adverse effects associated with all or several classes of anti-osteoporosis agents.

## Monitoring therapeutic response and long-term follow-up

Almost all the guidelines provided information on the role of repeated measurements of BMD and biochemical markers of bone turnover in monitoring. Some specified intervals for repeating tests (Table 3). Overall, there was limited guidance on making long-term management plans and providing them to the patient or primary care provider. Only two guidelines explicitly stated the need for a long-term plan, while 8 others implied the need for such planning.

## Treatment duration

Duration of treatment was specified in 13 guidelines and discussed very generally in two others. Most guidelines advised using bisphosphonates for 3–5 years before reassessing to determine whether to continue or

**Table 3** Recommendations for timing of bone densitometry in follow-up

Guideline	Mode	First test (if stated separately)	Intervals for repeat tests (if stated)
Australia	DXA	–	≥ 2 years when considering efficacy of treatment, risk assessment or decision to change or interrupt treatment Every 1 year in patients at high risk
China (Orthopedic)	DXA	1 year after starting treatment	–
China (CSOBMR)	Unspecified (bone density measurement)	1 year after starting or changing treatment	Every 1–2 years when effect has stabilized
China (Geriatrics)	DXA or QCT (if available)	–	Unspecified (Monitor efficacy)
	Biochemical markers of bone turnover	–	Every 3–6 months
Chinese Taipei	DXA	2 years after starting treatment < 2 years after starting treatment in patients with glucocorticoid-induced osteoporosis	–
Hong Kong SAR	BMD (not specified)	1–2 years after starting treatment in patients treated with antiresorptive treatment 1 year after starting treatment in patients treated with bone-forming agents	2–3 after therapeutic effect established
India (IMS)	DXA (use same DXA machine)	–	2 years
India (ISBMR)	DXA (if available)	–	2 years
Indonesia	BMD (not specified)	–	1–2 to evaluate treatment response (defined as stable over 1 year)
Japan	BMD (not specified)	1 year after starting treatment	> 1 year (unspecified)—after 1 year's treatment with bisphosphonates, intervals longer than 1 year needed to see change in BMD
Malaysia	DXA	Not specified	Not specified (Monitoring the effect of therapy)
New Zealand	BMD (not specified)	4–5 years after starting treatment to determine whether bisphosphonates treatment should continue	≥ 3 years (intervals < 3 years not recommended in most patients)
Singapore	DXA	1–2 years after starting treatment to establish clinical effectiveness	Every 2–3 years after clinical effectiveness established
South Korea	DXA	–	Every 1 year until normal BMD (T-score > – 1.0) 2 years after previous normal BMD
Thailand	DXA (Use same axial DXA analyzer)	–	> 1 year
Vietnam	Not specified	1–2 years	1–2 years

BMD bone mineral density, DXA dual-energy X-ray absorptiometry, QCT quantitative computed tomography

discontinue with observation (“drug holiday”), based on assessment of treatment response and fracture risk. Another guideline recommended continuing bisphosphonate therapy for 5–10 years before reconsideration. Several guidelines gave detailed guidance based on risk assessment. Three guidelines recommended that teriparatide treatment should not exceed 2 years, while one guideline recommended 3 years of treatment with teriparatide. Of the four guidelines that discussed HRT and mentioned initiation of, and duration of therapy with it, one (Australia) recommended that its long-term

use is not recommended. The Hong Kong SAR guideline recommended that patients should be adequately counselled on the risks and benefits of long-term use (beyond 3–5 years for combined estrogen-progesterone therapy and beyond 7 years for Estrogen alone therapy). The Indian Menopause Society guideline recommended it as first line therapy for women with menopausal symptoms for up to 10 years after menopause and specifically stated that HRT should not be started solely for bone protection after 10 years of menopause. The guidance from Singapore specified that menopausal hormone

therapy can be considered for prevention of osteoporosis and fragility fractures in women who experience early menopause and that it can be continued until the normal age of menopause unless contraindicated. Of the two guidelines that mentioned duration of denosumab therapy, one recommended long-term use and the other recommended reevaluation of fracture risk after 5–10 years.

### Adherence

Nine guidelines made specific recommendations on assessing and encouraging adherence.

### Falls prevention programs

Five guidelines made specific recommendations for referral to falls prevention programs. A further three guidelines provided detailed commentary on falls risk assessment.

### Integration

Overall, there was limited commentary on the need to develop a long-term management plan and provide it to the primary care provider and/or the patient. Only two guidelines explicitly referred to the need for a long-term care plan, while eight others implied that this was needed.

Though not specifically referring to the concept of integration and long-term planning, one guideline (South Korea) recommended the development of a secondary fracture prevention program that would be practical and suitable for their country to reduce re-fracture rates.

### Quality

In general, there was limited commentary on audit of practice against standards, or on continuing professional development and learning that is required. One guideline (Chinese Taipei) advocated benchmarking the performance of FLSs against the IOF Capture the Fracture® best-practice framework standards [40]. Another (New Zealand) recommended auditing against national clinical standards for FLSs. One guideline (Malaysia) included an audit question to assess post-hip fracture osteoporosis care. The need for a national hip fracture registry was noted in one guideline (India). Several guidelines identified dissemination of clinical practice guidelines and ongoing continuing professional development as priorities for healthcare professionals involved in the provision of care for people living with osteoporosis.

## Conclusions of the comparative analysis of existing guidelines

The 5IQ analysis confirmed previous anecdotal findings of marked heterogeneity among clinical practice guidelines for osteoporosis in the Asia-Pacific region—notably in guidance on risk factors, the use of biochemical bone turnover markers, self-care information for patients, indications for osteoporosis treatment, the use of fracture risk assessment tools, and protocols for monitoring treatment. Minimal guidance was provided on long-term management plans. Few mentioned strategies and systems for ensuring clinical quality improvement.

## Outcomes of the Delphi process

The surveys were sent to current APCO members ( $n = 39$ ), of whom 29 participated in one or more of the four rounds. Respondents were drawn from 18 countries/regions viz Australia (3), Brunei (1), China (1), Hong Kong SAR (2), Chinese Taipei (1), India (3), Japan (1), Korea (1), Malaysia (2), Myanmar (1), Nepal (1), New Zealand (3), Pakistan (1), Philippines (1), Singapore (2), Sri Lanka (1), Thailand (2), and Vietnam (1) and from the International Osteoporosis Foundation (1).

### Round 1

Consensus was reached on the inclusion of clinical standards on the following components (i.e.,  $\geq 75\%$  rated its inclusion as important or extremely important (Table 4)):

- Identification of individuals with fragility fractures
- Identification of individuals with common risk factors for osteoporosis, such as age 70 years or above, early menopause, excessive alcohol intake, family history, height loss, low body mass index/weight, prolonged immobility, smoking
- Identification of individuals who take medicines associated with bone loss and/or increased fracture risk
- Identification of individuals with conditions associated with bone loss and/or increased fracture risk
- Use of risk assessment tools
- Vertebral fracture assessment
- Falls risk assessment
- Information provided to patients on self-care, such as calcium intake, sun exposure, the relationship between osteoporosis and fracture risk, exercise
- Indications for treatment to include hip fracture, vertebral fracture, and non-hip non-vertebral fracture
- Recommendations for pharmacological interventions for specific patient subgroups
- Recommendations for nonpharmacological interventions

**Table 4** Delphi round 1 responses

Component	Inclusion of standard on this component					Consensus (% rating as extremely or very important, i.e., $\geq 75\%$ )
	Extremely important	Very important	Somewhat important	Not so important	Not at all important	
<b>Identification</b>						
Fragility fracture	22	3	0	0	0	Yes (100%)
Risk factors for osteoporosis	12	10	2	0	0	Yes (92%)
Medicines associated with bone loss/fracture risk	7	15	3	0	0	Yes (88%)
Medical conditions associated with bone loss/fracture risk	5	16	4	0	0	Yes (84%)
<b>Investigation</b>						
Biochemistry	5	11	8	1	0	No
BMD testing	8	9	8	0	0	No
Risk assessment tools	12	9	3	1	0	Yes (84%)
Vertebral fracture assessment	14	5	4	1	0	Yes (79%)
Falls risk assessment	9	13	3	0	0	Yes (88%)
Specialist referral	4	11	8	2	0	No
Information for patients	14	7	4	0	0	Yes (84%)
<b>Intervention</b>						
Indications—see Table 5						N/A
Pharmacological	10	12	3	0	0	Yes (88%)
Non-pharmacological	4	16	4	1	0	Yes (80%)
Side effects	6	15	3	1	0	Yes (84%)
Monitoring effect	11	11	3	0	0	Yes (88%)
Duration	13	8	4	0	0	Yes (84%)
Adherence	8	12	3	2	0	Yes (80%)
Falls programs	5	13	6	0	0	No
<b>Integration</b>						
Long-term management plans	11	9	4	1	0	Yes (80%)
<b>Quality</b>						
Adherence to guideline-based care	10	12	2	1	0	Yes (88%)

Respondents' priority ratings for each of the key components identified in existing clinical practice guidelines. Consensus was defined as a rating of extremely important or very important by at least 75% of respondents

- Description of side effects of pharmacological treatments
- Monitoring of pharmacological treatment
- Duration of pharmacological treatment
- Adherence to pharmacological treatment
- Provision of long-term management plans to patients and/or primary care providers
- Quality metrics for adherence to guideline-based care.


Sixteen standards were drafted based on this consensus. Although the initial intention was to draft levels of attainment for each standard, only a few standards proved amenable to this approach after collating respondents' comments on priority rankings and levels of attainment. Levels of attainment were therefore *drafted* initially for

five standards viz for those on (a) identification of fragility fractures, (b) identification of patients with common risk factors, (c) investigation of vertebral fractures, (d) assessment of adherence to pharmacological treatment, and (e) quality metrics to assess clinical adherence to guidelines. Each of these five standards had three levels of attainment, stratified according to degree of difficulty or feasibility of implementation.

## Round 2

Consensus was reached (i.e.,  $\geq 75\%$  of respondents strongly agreed or agreed) on the wording of all 16 standards (Fig. 1). Agreement was unanimous or nearly so ( $> 90\%$  agreement) for the wording of draft standards on:

**Fig. 1** Delphi second-round consensus on wording of standards. The proportion of respondents who voted “strongly agree” or “agree” on the wording of 16 draft clinical practice standards



- Proactive case identification based on medicines associated with bone loss/increased fracture risk
- The use of country-specific fracture risk assessment tools, vertebral fracture assessment, and falls risk assessment
- Duration of pharmacological treatment and adherence to pharmacological treatment

- Long-term management plans
- Metrics for adherence to guidelines

Diversity of opinion was greatest for the wording of the draft standard on proactive case identification based on

**Table 5** Delphi round 1 responses: indications for initiating osteoporosis-specific treatment

Indications	Selected ( <i>n</i> )		Consensus (% rating as extremely or very important, i.e., $\geq 75\%$ )
	Yes	No	
Hip fracture	24	1	Yes (96%)
Vertebral fracture	24	1	Yes (96%)
Non-hip non-vertebral fracture	20	5	Yes (80%)
BMD T-score $\leq -2.5$ SD	18	7	No
Osteopenia + FRAX® $\geq 3\%$ hip or $\geq 20\%$ MOF	11	14	No
Osteopenia + RFs or eligible by OSTA or SCORE	7	18	No
Osteopenia + $\geq 10$ years post menopause	3	23	No
FRAX® or Garvan $\geq 3\%$ hip or $\geq 20\%$ MOF	9	16	No
Eligible by OSTA, MORES, or SCORE	1	24	No
QCT	2	23	No
Height loss $> 4$ cm	11	14	No
Androgen deprivation therapy	10	6	No
Aromatase inhibitor treatment	9	16	No
Glucocorticoid treatment	17	8	No
Country-specific thresholds	14	11	No

*BMD* bone mineral density, *MORES* Male Osteoporosis Risk Estimation Score, *OSTA* Self-Assessment Tool for Asians, *SCORE* Simple Calculated Osteoporosis Risk Estimation, *QCT* quantitative computed tomography

The percentage of APCO member respondents who rated each of the proposed indications for initiating osteoporosis treatment identified in existing clinical practice guidelines, as extremely or very important for inclusion in APCO clinical practice standard 9

common risk factors, although consensus was reached. The volume of comments (excluding minor editing suggestions) was highest for the standards on, medicines associated with risk, assessment of vertebral fractures, intervention thresholds for osteoporosis-specific therapies (Table 5), and assessment of adherence to pharmacological therapies.

**Draft standards from which levels of attainment were subsequently removed** Of the five standards that had levels of attainment drafted, consensus was reached on the wording of all except those on identification of patients with common risk factors (69.6% voted “strongly agree” or “agree”). For this standard, the proposed levels were as follows: Level 1—identification of individuals with common risk factors to include alcohol intake of  $\geq 2$  units per day, a family history of osteoporosis or fragility fracture,  $BMI \leq 20 \text{ kg/m}^2$ , or a history of smoking. Level 2—identification of individuals with Level 1 common risk factors *plus* age  $\geq 70$  years and/or height loss of  $\geq 4$  cm compared to maximum height as a young adult. Level 3—identification of individuals with Level 1 and 2 common risk factors *plus* early menopause (defined as occurring before 45 years) and/or prolonged immobility. Issues noted by respondents for this included the difficulty of implementing these levels of attainment and the omission of particular risk factors (prolonged glucocorticoid use and falls risk). There were also concerns about defining levels according to numbers of risk factors, with suggestions that the levels should instead represent increasing percentages of at-risk patients identified, or be defined by the approach to case-finding, e.g., whether at-risk individuals are identified systematically or otherwise. Given the significant discordance among the participants, it was therefore decided by consensus that this standard would not be amenable to levels of attainment.

The threshold for consensus (75%) was reached on the wording of draft attainment levels for the standard on assessment of adherence to pharmacological therapy, but levels were not retained after several respondents queried the selection of cut-points and the feasibility of implementing the levels.

Thus, out of the five standards that were originally drafted with levels of attainment, we retained the levels in only three of them. These three standards were on (a) identification of fragility fractures, (b) investigation of vertebral fractures, and (c) quality metrics to assess clinical adherence to guidelines.

Members proposed alternative wordings for several standards and levels of attainment, including several of those that reached consensus. The chairperson and project manager analyzed the suggestions and drafted amendments.

### Round 3

Consensus was achieved on all the proposed amendments, involving six standards, and levels of attainment for two

standards. At the end of this round, consensus had been reached on the final Framework of minimum clinical standards.

### Round 4

There were no objections to the minor amendments proposed to improve clarity and precision of the wording of some of the standards.

## APCO Framework

**Clinical standard 1** Men and women who sustain a fragility fracture should be systematically and proactively identified to undergo assessment of bone health and, where appropriate, falls risk.

Levels of attainment for clinical standard 1:

- Level 1: Individuals who sustain hip fractures should be identified.
- Level 2: Individuals who sustain hip and/or clinical vertebral fractures should be identified.
- Level 3: Individuals who sustain hip, clinical and/or morphometric vertebral, and/or non-hip, non-vertebral major osteoporotic fractures should be identified.

**Clinical standard 2** Men and women with common risk factors for osteoporosis should be proactively identified to undergo assessment of bone health and, where appropriate, falls risk. A sex-specific age threshold for assessment should be determined for each country or region and should be included in new or revised osteoporosis clinical guidelines.

**Clinical standard 3** Men and women who take medicines that are associated with bone loss and/or increased fracture risk should be proactively identified to undergo assessment of bone health and, where appropriate, falls risk. A commentary should be included in new or revised osteoporosis clinical guidelines to highlight commonly used medicines that are associated with bone loss and/or increased fracture risk.

**Clinical standard 4** Men and women who have conditions associated with bone loss and/or increased fracture risk should be proactively identified to undergo assessment of bone health. A commentary should be included in new or revised osteoporosis clinical guidelines to highlight common prevalent conditions in the country or region.

**Clinical standard 5** The use of country-specific (if available) fracture risk assessment tools (e.g., FRAX®, Garvan, etc.) or osteoporosis screening tools (e.g., OSTA) should be a

standard component of investigation of an individual's bone health and prediction of future fracture risk and/or osteoporosis risk.

**Clinical standard 6** Assessment for presence of vertebral fracture(s) either by X-ray (or other radiological investigations such as CT or MRI), or by DXA-based VFA should be a standard component of investigation of osteoporosis and prediction of future fracture risk.

Levels of attainment for clinical standard 6:

- Level 1: Individuals presenting with clinical vertebral fractures should undergo assessment for osteoporosis.
- Level 2: Individuals with incidentally detected vertebral fractures on X-ray and/or other radiological investigations should be assessed for osteoporosis.
- Level 3: Individuals being assessed for osteoporosis should undergo spinal imaging with X-ray or other appropriate radiological modalities, or with DXA-based VFA.

**Clinical standard 7** A falls risk assessment should be a standard component of investigation of an individual's future fracture risk.

**Clinical standard 8** In order to engage individuals in their own care, information should be provided on calcium and vitamin D intake, sun exposure, exercise, and the relationship between osteoporosis and fracture risk.

**Clinical standard 9** The decision to treat with osteoporosis-specific therapies and the choice of therapy should be informed as much as possible by country-specific and cost-effective intervention thresholds. Intervention thresholds that can be considered include:

- History of fragility fracture
- BMD T-score  $\leq -2.5$  S.D.
- High fracture risk as assessed by country-specific intervention thresholds

**Clinical standard 10** New or revised osteoporosis clinical guidelines should include a commentary on the common side effects of pharmacological treatments that are recommended in the guidelines.

**Clinical standard 11** New or revised osteoporosis clinical guidelines should provide a commentary on monitoring of pharmacological treatments. This could include, e.g., the role of biochemical markers of bone turnover and bone mineral density measurement.

**Clinical standard 12** New or revised osteoporosis clinical guidelines should provide a commentary on the duration of pharmacological treatments that are recommended in the guidelines. This should include a discussion on the appropriate order of sequential treatment with available therapies and the role of "drug holidays."

**Clinical standard 13** Assessment of adherence to pharmacological treatments that are recommended in new or revised osteoporosis clinical guidelines should be undertaken on an ongoing basis after initiation of therapy, and appropriate corrective action be taken if treated individuals have become non-adherent.

**Clinical standard 14** New and revised osteoporosis clinical guidelines should provide a commentary on recommended non-pharmacological interventions, such as exercise and nutrition (including dietary calcium intake) and other non-pharmacological interventions (e.g., hip protectors).

**Clinical standard 15** In collaboration with the patient, the treating clinician (hospital specialist and/or primary care provider) should develop a long-term management plan that provides recommendations on pharmacological and non-pharmacological interventions to improve bone health and, where appropriate, measures to reduce falls risk.

**Clinical standard 16** New or revised osteoporosis clinical guidelines should provide a commentary on what quality metrics should be in place to assess adherence with guideline-based care.

Levels of attainment for clinical standard 16:

- Level 1: Conduct a local "pathfinder audit" in a hospital or primary care practice to assess adherence to APCO Framework clinical standards 1–9, 13, and 15.
- Level 2: Contribute to a local fracture/osteoporosis registry.
- Level 3: Contribute to a fracture/osteoporosis registry for your country or region.

The clinical standards are shown in Appendix 3.

## Discussion

The 5IQ analysis of the multiple clinical practice guidelines on osteoporosis from Asia-Pacific countries and regions confirmed our understanding, based on previous anecdotal reports, that existing guidelines were markedly heterogeneous in terms of their scope and recommendations. The findings enabled APCO members to prioritize and select elements through the Delphi consensus method. The resulting

minimum standards for care for the Asia-Pacific region are relevant, pragmatic, and feasible to implement.

### Application of the Framework to clinical practice guidelines

Clinicians need information that is clear and readily accessible. Osteoporosis guidelines should clearly articulate which individuals should be identified for assessment, the investigations that should be offered, appropriate indications for treatment, the pharmacological treatments and other interventions that should be offered to specific patient groups, information on self-management that should be provided to patients, how the levels of healthcare systems should be integrated to ensure seamless care, and how the quality of osteoporosis healthcare services should be monitored and improved.

APCO's goal is that all new or revised clinical practice guidelines for prevention, diagnosis, and management of osteoporosis in the Asia-Pacific region will:

- be consistent with the scope proposed in the Framework,
- promote the standards of care recommended in the Framework, and
- recommend local benchmarking against the standards recommended in the Framework.

To achieve this, APCO members will identify opportunities in their individual countries and regions to share the Framework with colleagues and organizations involved in clinical practice guideline development. The clinical standards will be distributed in a modular format that should allow easy adoption at the individual health care facility, national or regional level.

### Benchmarking and audit activities

Benchmarking against specific clinical standards is already used to measure the performance of osteoporosis care. Benchmarking of care for secondary prevention of fragility fractures is a component of the IOF Capture the Fracture® program [40], and of national fracture liaison service standards based on the 5IQ model [7–9]. Hip fracture registries, that have been established in several countries, also enable benchmarking of acute perioperative care and secondary fracture prevention after hip fracture [41–46].

After the Framework is published and it is disseminated, audit against benchmarks derived from the Framework will be undertaken at various healthcare system levels, ranging from individual healthcare provider or primary care medical practice level to hospital units, groups of hospitals, regions, or nations. The scale of activities can range from audit based on one selected standard to audit against several standards.

Initially, APCO members will be invited to undertake “pathfinder audits” in their hospitals to establish baseline levels of adherence with selected standards, such as BMD testing rates and osteoporosis treatment initiated during the episode of care. Follow-up audits will be conducted 12 months later to measure effects of implementing the standards.

### Recently established and emerging themes in osteoporosis care

Several developments that significantly impact strategies for the management of osteoporosis have recently been brought to the forefront of medical management of osteoporosis. Predictably, the 5IQ analysis found that these were either not incorporated into existing guidelines or mentioned only briefly. However, they have enormous implications and potential to change the treatment landscape of osteoporosis and therefore need to be highlighted.

These include but are not limited to:

- systematic integration of case identification and management at all levels of health systems, including acute care services, when patients present with fractures (e.g., through FLSs),
- stratification of individual fracture risk,
- the role of sequential therapies, and
- the use of health economics to inform intervention thresholds and indications for specific classes of osteoporosis therapies.

### Fracture liaison services

Up to 50% of patients with a hip fracture have already sustained fractures at other skeletal sites during the previous months or years [47, 48]. A prior fracture at any site is associated with a doubling of future fracture [49, 50] and mortality [51] risks. Accordingly, these “signal” or “sentinel” fractures should alert healthcare providers to the opportunity for secondary fracture prevention.

Over the past decade and a half, coordinated post-fracture models of care have been designed to ensure that healthcare providers consistently respond to the first fracture to prevent the second and subsequent fractures [48]. These are generally hospital-based, but involvement of primary care physicians is also important to ensure continuity of care [52, 53]. Components of effective FLSs include multidisciplinary involvement, dedicated case managers and clinician champions, regular assessment and follow-up, multifaceted interventions, and patient education [54].

Fracture liaison service programs significantly increase rates of BMD testing, initiation of osteoporosis treatment, adherence to treatment, and reduce refracture incidence and

mortality rates, compared with usual care [54, 55]. They are cost-effective in comparison with usual care or no treatment, regardless of the program intensity or the country [55]. The IOF strongly promotes the concept of FLSs through its global Capture the Fracture® initiative [40]. This initiative has set an international benchmark for FLSs by defining 13 globally endorsed standards for service delivery.

### Fracture liaison services in the Asia-Pacific and reference to these in the extant guidelines

The number of FLSs in the Asia-Pacific region is rapidly increasing. Analyses of indigenous fracture liaison programs have been conducted in several countries and regions in the Asia-Pacific region including Australia [56], China [57, 58], Chinese Taipei [59], Hong Kong SAR [60], Singapore [61], Japan [62–64], New Zealand [65], South Korea [66–69], and Thailand [70]. In 2017, the fracture liaison service consensus meeting held in Taipei concluded that the 13 Best Practice Framework Standards of the IOF's Capture the Fracture® campaign [40] were generally applicable in the Asia-Pacific region (albeit with minor modifications). As of 17 September 2020, 111 FLSs from the Asia-Pacific region are included on the IOF Global Map of Best Practice (<https://www.capturethefracture.org/map-of-best-practice>). Eighty-four have been fully evaluated, of which 19 have been awarded a Gold star. These include FLSs from Australia, Japan, New Zealand, Singapore, Taiwan, and Thailand.

Despite this burgeoning interest, the 5IQ analysis revealed that only four guidelines in the Asia-Pacific region advocated the role of FLSs, suggesting that the crucial role of secondary fracture prevention is still sadly under-recognized among guideline developers and policy makers in the Asia-Pacific [52]. Two recent initiatives are, however, expected to enable more widespread adoption of FLSs in the region: the FLS tool box for Asia-Pacific developed by the Asia-Pacific Bone Academy Fracture Liaison Service Focus Group [71], and the Capture the Fracture® Partnership launched by the IOF (<https://www.capturethefracture.org/capture-fracture-partnership>), which includes several countries in the Asia Pacific region.

### Risk stratification

Upon the knowledge that “fractures beget fractures” [47, 49, 50] has subsequently come the understanding that the risk of a subsequent fragility fracture is particularly acute immediately after the sentinel or the index fracture and that this risk wanes progressively with time [72–78]. This very high fracture risk in the 1 to 2 years after the index fracture has been termed “imminent risk” [79, 80] and appears to be age-dependent, with the transient effect of increased risk being more evident at older ages [76]. The ratio of 10-year fracture probability after a recent fragility fracture to that after a fracture,

irrespective of its site or recency, has been termed the probability ratio or adjustment ratio. Probability ratios that provide adjustments to conventional FRAX® estimates for recency of sentinel fractures have now been derived, though how they will be included in the FRAX® algorithm is still being debated [81].

Other factors can also contribute to, or result in, a very high fracture risk. The simultaneous presence of multiple risk factors (e.g., family history of fracture, glucocorticoid use) can additively contribute to fracture probabilities and shift fracture risk categories to higher strata of risk [30]. Individuals have also been somewhat arbitrarily designated as very high risk if they have fractures while on approved osteoporosis therapy, have multiple prevalent fractures or fractures while on drugs causing skeletal harm such as glucocorticoids, have very low T-score (e.g.,  $< -3.0$ ), have high risk for falls or a history of falls, or have a FRAX® probability for major osteoporosis fracture  $> 30\%$ , or hip fracture  $> 4.5\%$  over a 10-year period [82].

This concept of stratification of osteoporotic fracture risk that may enable or guide the choice of therapeutic agent is gaining traction globally. Those at higher risk may require initiation of treatment with more potent therapies such as an anabolic agent. For those at low risk, a decision will need to be made on whether therapy with an anti-osteoporosis agent is even indicated. Updated position papers and guidelines published by the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the International Osteoporosis Foundation (IOF) [80] and by the American Association of Clinical Endocrinologists (AACE) [82] provide recommendations for this stratification of risk. The ESCEO/IOF position paper applies age-specific thresholds to define high versus very high risk, while the AACE guidelines suggest an arbitrarily decided fixed threshold as well as the presence of certain pre-defined risk factors as described previously [80, 82].

At a regional and national level, these recommendations will have to be reviewed to determine the relevance to local practices and to see whether they offer tangible benefits to patients. Some challenges to implementation of these guidelines in the Asia-Pacific would need to be considered. The FRAX® thresholds that are recommended in the AACE guidelines are likely only applicable to the USA. While FRAX® has been validated in many Asian countries, most of them have not implemented specific intervention thresholds for use yet. Recommendations also need to consider local reimbursement criteria, which often dictate eligibility criteria for pharmacological treatment options.

### Sequential therapies in osteoporosis

Osteoporosis is a chronic condition. Therefore, patients with osteoporosis need a long-term, personalized management plan, with many patients requiring multiple anti-osteoporosis medications during their lifetime. The specific and individualized

treatment plan traditionally has involved initiation of therapy with an antiresorptive agent. Most of the extant guidelines in the Asia-Pacific region also favor this approach. However, there is evidence for a stronger anti-fracture efficacy of bone-forming treatments compared to antiresorptive ones from two clinical trials in patients with severe osteoporosis [83, 84] and for a blunted/delayed BMD response to bone-forming treatment, with prior antiresorptive use, though this effect somewhat depends on the potency of the antiresorptive agent [85–87].

In certain scenarios, a deleterious effect on BMD is seen in patients previously treated with antiresorptive agents who are then switched to an anabolic agent [88]. In contrast, sequential therapy with an anabolic agent followed by an antiresorptive agent appears largely to be associated with maintenance or continued increase in BMD [88] and continued reduction in fractures [84, 89].

This has resulted in increasing interest in sequential treatment with an anabolic agent given as first-line treatment in the very-high-risk fracture patient, whose fracture risk needs to be addressed quickly and in whom BMD needs to be improved quickly and as much as possible. However, the fact that this may not always be possible, due to restrictions in reimbursement criteria and limitations imposed by guidelines, should be considered before advocating large-scale adoption of such recommendations.

### Health economics

Health economic analysis is playing an increasingly important role to inform the relative value of osteoporosis therapies and to help determine how best to allocate finite health care resources. The development of absolute fracture risk-based assessment and intervention thresholds has led also to the exploration of cost-effectiveness of interventions along the lines of fracture probability. A significant body of evidence now exists to show that anti-osteoporosis therapies are cost-effective in women at high risk of fracture [90].

However, the cost-effectiveness of various pharmacological therapies is determined in part by the costs and benefits of treatment. Intervention thresholds will also vary, since they depend critically on country- and region-specific factors such as reimbursement issues, health economic assessment, willingness to pay for healthcare, and access to DXA scanning. Due to this vast heterogeneity in epidemiologic and economic characteristics between countries, such thresholds should be country-specific. In the USA, a 10-year absolute hip fracture probability of 3% and its equivalent major osteoporotic fracture probability of 20% have been considered as cost-effective intervention thresholds [39]. Various other major osteoporotic fracture risk fixed intervention thresholds ranging from 7 to 15% have been deemed to be cost-effective in other countries [91, 92]. In the UK, age-dependent FRAX®-based

intervention thresholds have been shown to provide clinically appropriate access to treatment as well as to be cost-effective [93].

Given the evidence supporting initial treatment of patients at very high risk of fragility fracture with an anabolic agent followed by consolidating the effect of these agents with antiresorptive agents, health economic appraisals exploring the cost-effectiveness of such sequential therapies are also slowly emerging [94].

Health economic evaluation studies in osteoporosis are few in the Asia-Pacific region. Robust studies have been conducted in a few countries including Singapore [95], China [96, 97], Japan [98, 99], and Australia [100]. These studies have employed different modeling strategies and have explored cost-effectiveness of fracture intervention thresholds as well as of various osteoporosis medications. The varying results obtained from these studies highlight the crucial differences in economic, epidemiological, and clinical practice factors between the countries in the vast region that is the Asia-Pacific.

### Conclusions

The APCO Framework represents the first consensus minimum standards of osteoporosis care, purpose-developed by clinicians for the whole of the Asia-Pacific region. Developing it through a comparative analysis of extant guidelines in the Asia Pacific region and through the consensus of experts from diverse health care systems enables the recommendations to be practical and relevant to the unique needs of this vast and populous region. However, publishing and disseminating the Framework is only half the battle won. The success of the Framework will be discernible only after the standards have been implemented throughout the region and its efficacy has been systematically measured.

The Framework provides accessible, clear, and feasible recommendations for osteoporosis care in the Asia Pacific region. It is hoped that the Framework will inform national societies, guideline development authorities, and health care policy makers in the development of new guidelines and promote the revision of existing guidelines. The principles and processes behind its development can be translated and adapted to other regions of the world that also face similar socioeconomic diversity and heterogeneity of healthcare resources. The implementation of the Framework, or similar sets of standards of care inspired by it, is thus expected to significantly reduce the burden of osteoporosis, not only in the Asia Pacific region, but also globally.

Emerging concepts in osteoporosis care and technologies should also be keenly followed and should be incorporated into new and revised guidelines after careful deliberation on their applicability to local health care practices.

**Acknowledgments** Linguistico (Sydney, Australia) provided English translations of the four Chinese clinical practice guidelines. Dr. David Kim performed data extraction for the South Korean guidelines. Editorial assistance and writing support were provided by Ms Jennifer Harman of Meducation Australia Pty. Ltd., contracted by APCO for the purpose.

APCO executive committee

Dr. Manju Chandran (Chairperson), Singapore General Hospital, Singapore

Dr. Philippe Halbout, International Osteoporosis Foundation, Nyon, Switzerland

Dr. Greg Lyubomirsky, Osteoporosis Australia, Sydney, Australia

Professor Peter Ebeling, Monash Health, Melbourne, Australia

Professor Tuan V. Nguyen, Garvan Institute of Medical Research, Sydney, Australia

Professor Xia Weibo, Peking Union Medical College Hospital, Beijing, China

Dr. Cae Tolman, Amgen Asia, Industry Representative, Hong Kong, Hong Kong SAR (non-voting member)

Dr. Tiu Kwok Leung, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR

Professor Sanjay K. Bhadada, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Mr. Paul Mitchell, APCO Project Manager, Synthesis Medical NZ Limited, Auckland, New Zealand (non-voting member)

Dr. Nigel Gilchrist, Canterbury District Health Board, Christchurch, New Zealand

Dr. Aysha Habib Khan, Aga Khan University, Karachi, Pakistan

Dr. Sarath Lekamwasam, University of Ruhuna, Matara, Sri Lanka

APCO members: Dr. Tanawat Amphansap (Police General Hospital, Thailand), Professor Manoj Chadha (Hinduja Hospital and Research Centre, India), Professor Ding-Chen Chan (National Taiwan University Hospital, Chinese Taipei), Professor Yoon-Sok Chung (Ajou University School of Medicine, Republic of Korea), Dr. Hew Fen Lee (Subang Jaya Medical Centre, Malaysia), Professor Kee Hyung Rhyu (Kyung Hee University, Republic of Korea), Dr. Lan T. Ho-Pham (Pham Ngoc Thach University of Medicine, Vietnam), Professor Tint Swe Latt (Shwe Baho Hospital, Myanmar), Dr. Edith Lau (Hong Kong Orthopaedic and Osteoporosis Center for Treatment and Research, Hong Kong SAR), Dr. Lau Tang Ching (National University Hospital, Singapore), Dr. Dong Ock Lee (National Cancer Center, Republic of Korea), Dr. Lee Joon Kiong (Beacon International Specialist Centre, Malaysia), Professor Liu Jianmin (Shanghai Ruijin Hospital, China), Professor Leilani B. Mercado-Asis (University of Santo Tomas), Professor Ambrish Mithal (Max Healthcare - Pan-Max, India), Dr. Dipendra Pandey (National Trauma Centre, Nepal), Professor Ian R. Reid (University of Auckland, New Zealand), Professor Atsushi Suzuki (Fujita Health University, Japan), Professor Akira Taguchi (Matsumoto Dental University, Japan), Associate Professor Vu Thanh Thuy (Bach Mai Hospital, Vietnam), Dr. Tet Tun Chit (East Yangon General Hospital, Myanmar), Dr. Gunawan Tirtarahardja (Indonesian Osteoporosis Association), Dr. Thanut Valleenukul (Bhumibol Adulyadej Hospital, Thailand), Dr. Yung Chee Kwang (Raja Isteri Pengiran Anak Saleha Hospital, Brunei Darussalam), Dr. Zhao Yanling (Beijing United Family Hospital, China).

**Funding** Amgen Asia provided financial support to fund secretariat function, event management, and communication activities for the formation of APCO. All APCO members, except the Project manager, contribute to APCO on a purely voluntary basis and are not paid/compensated for their time. The Project Manager, who is a paid consultant for APCO, assisted APCO with the 5IQ analysis and the formulation and processing of the

Delphi Questionnaires. The opinions and activities of APCO are not influenced by Amgen, nor did Amgen have any role in the writing of this manuscript.

**Data availability** Not applicable

## Compliance with ethical standards

**Conflict of interest** A Statement of Disclosure accompanies this submission.

Manju Chandran (MC): Chairperson of APCO. MC has received honoraria for lectures organized by DKSH, Amgen, and Zuellig Pharma, and for chairing advisory board meetings for Amgen.

Paul Mitchell (PM): PM has undertaken consultancy for governments, national and international osteoporosis societies, healthcare professional organizations and private sector companies relating to systematic approaches to fragility fracture care, and prevention since 2005. PM is a paid consultant for APCO.

Tanawat Amphansap (TA): TA has received honoraria for lectures organized by Amgen, DKSH, MSD, and Zuellig Pharma.

Manoj Chadha (MC): MC has received honorariums for serving on the steering committee of Amgen's South East Asia and India Bone Academy Board.

Ding-Chen Chan (DC) reports personal fees (consulting fees) from Amgen, Lotus, Eli-Lilly and Harvester Trading Co, Ltd.

Peter Ebeling (PE): PE has research funding from Amgen, Eli-Lilly, Novartis, and Alexion and has received honoraria from Amgen and Alexion.

Nigel Gilchrist (NG): NG has received research grants from Amgen.

Lau TC: has received honoraria for speaking at symposia and financial support for attending symposia by Amgen Pte. Ltd.

Lee JK: has received honoraria from Amgen, Mylan, and Zuellig Pharma for speaking at symposia, as member of advisory board and educational programs and workshops.

Tuan V. Nguyen (TVN) has received grant support from Amgen and honoraria for lectures and conference engagements from Novartis, MSD, Amgen, and Bridge Health Care.

Atsushi Suzuki (AS): AS has received research funding from Chugai Pharmaceutical Co. Ltd., Kowa Co. Ltd., Ono Pharmaceutical Co. Ltd., Taisho Pharmaceutical Co Ltd., and Takeda Pharmaceutical Co. Ltd., and has received symposium honoraria from Asahi Kasei Pharma Co., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Kyowa Kirin Co. Ltd., and Taisho Pharmaceutical Co. Ltd.

Thanut Valleenukul (TV) has received honoraria for lectures organized by Amgen

The following authors declare that they have no conflict of interest: Sanjay Bhadada (SB), Yoon-Sok Chung (YSC), Aysha Habib Khan (AHK), Philippe Halbout (PH), Hew FL, Lan T. H-P, Sarath Lekamwasam (SL), Greg Lyubomirsky (GL), Leilani B. Mercado-Asis (LBMA), Ambrish Mithal (AM), Dipendra Pandey (DP), Ian R. Reid (IRR), Tet Tun Chit (TTC), Tiu KL, Yung Ck, Zhao YL.

**Ethics approval** Not applicable

**Consent to participate** Not applicable

**Consent for publication** Not applicable

**Code availability** Not applicable

## Appendix 1 Template for extracting data from clinical practice guidelines (modified 5IQ model)

### Publication information and format

1. Country/region
2. Sponsor organization
3. Year
4. Number of pages
5. Review date
6. Guideline published in English (Yes/No)
7. Corresponding author (Yes/No)
8. Does the guideline include a flowchart/algorithm?

### Identification

1. Male, female, both male and female
2. Individuals who have sustained fragility fractures
  - a. Age threshold
  - b. Fracture types evaluated
  - c. Other comments relating to secondary fracture prevention
3. Individuals taking medicines to manage other conditions which are associated with bone loss and/or increased fracture risk:[10]
  - a. Androgen deprivation therapy
  - b. Anticoagulants
  - c. Anticonvulsants
  - d. Aromatase inhibitors
  - e. Calcineurin inhibitors
  - f. Glucocorticoids
  - g. Medroxyprogesterone acetate
  - h. Proton pump inhibitors
  - i. Selective serotonin reuptake inhibitors
  - j. Thiazolidinediones
  - k. Other medicines
4. Conditions associated with bone loss and/or increased fracture risk:[10]
  - a. Chronic obstructive pulmonary disease
  - b. Diabetes
  - c. Diseases of malabsorption
  - d. Dementia
  - e. Rheumatoid arthritis
  - f. HIV
  - g. Multiple myeloma
  - h. Untreated/uncontrolled hyperthyroidism
  - i. Other conditions
5. Other risk factors
  - a. Age 70 years or over
  - b. Early menopause
  - c. Excessive alcohol intake
  - e. Family history
  - f. Height loss
  - g. Low body mass index/weight
  - h. Prolonged immobility
  - i. Smoking
  - j. Other risk factors
  - k. Other comments on identification

(continued)

**Publication information and format****Investigation**

1. BMD testing, if available
2. Fracture risk calculators

- a. FRAX®
- b. Garvan
- c. IOF 1-minute test
- d. KKOS
- e. OSTA
- f. MORES
- g. QFracture
- h. SCORE

3. Vertebral fracture assessment by X-Ray or DXA
4. Falls risk assessment
5. Blood biochemistry

- a. Alkaline phosphatase
- b. Calcium
- c. Creatinine
- d. Osteocalcin
- e. uNTX
- g. PINP
- h. PTH
- i. Vitamin D
- j. Other assays

6. Referral to specialist

**Information**

1. Information on calcium intake
2. Information relating to sun exposure
3. Information relating to osteoporosis and fracture risk
4. Information relating to exercise
5. Other information

**Intervention**

1. Which patient groups are indicated for treatment?

- a. Hip fracture
  - b. Vertebral fracture
  - c. Non-hip, non-vertebral fracture
  - d. BMD T-Score  $\leq -2.5$  SD
  - e. Osteopenia + FRAX  $\geq 3\%$  Hip or  $\geq 20\%$  MOF
  - f. Osteopenia + RFs or eligible by OSTA or SCORE
  - g. Osteopenia +  $\geq 10$  years postmenopausal
  - h. FRAX or Garvan  $\geq 3\%$  Hip or  $\geq 20\%$  MOF
  - i. Eligible by OSTA, MORES or SCORE
  - j. QCT  $< 80$  mg/cm<sup>3</sup>
  - k. Height loss  $> 4$  cm
  - l. Androgen deprivation therapy use
  - m. Aromatase inhibitor use
  - n. Glucocorticoid use
- a. Bisphosphonates (oral, IV)
  - b. Calcium
  - c. HRT
  - d. Monoclonal antibodies (denosumab, romosozumab)
  - e. Parathyroid hormone analogues (abaloparatide, teriparatide)

2. Which treatment options are recommended?

(continued)

**Publication information and format**

- f. Selective estrogen receptor modulators (raloxifene, tamoxifen, toremifene)
- g. Vitamin D
- h. Other treatment options
3. Are recommendations made on monitoring treatment?
4. Are recommendations made on treatment duration?
5. Are recommendations made on checking adherence with treatment?
6. Comments on side effects
7. Comments on referral to falls prevention programs
8. Comments relating to other interventions

**Integration**

1. Are recommendations made to provide the patient with a long-term management plan?
2. Are recommendations made to provide the patient's primary care provider with a long-term management plan?

**Quality**

1. Does the guideline advocate audit of care provision against clinical care standards?
2. Does the guideline advocate healthcare providers maintain ongoing professional medical education relating to osteoporosis?

## Appendix 2 Delphi Round 1 questionnaire toward consensus on clinical standards for osteoporosis

### Domain 1: Notable findings from the 5IQ Comparative analysis of osteoporosis clinical guidelines from across the Asia Pacific region

This domain of the questionnaire includes a series of open-ended questions which invite you to share your opinions on the most notable findings of the 5IQ analysis report.

5IQ item	Question	Options
Identification	Considering the groups of individuals that the various guidelines recommend should be identified for bone health assessment, what are the most notable findings in the analysis? (You can indicate more than one)	[Free text]
Investigation	Considering the investigations that the various guidelines recommend should be undertaken, what are the most notable findings in the analysis?	[Free text]
Information	Considering the types of information that should be imparted to patients to engage them in their care, which are the most notable points identified by the analysis in your view?	[Free text]
Intervention	Considering the <b>indications</b> for treatment that are advocated, what are the most notable findings identified by the analysis in your view?	[Free text]
	Considering the <b>pharmacological</b> treatments for specific patient groups identified by the analysis, what are the most notable findings in your view?	[Free text]
	Considering the findings of the analysis related to <b>falls prevention</b> , what are the most notable in your view?	[Free text]
Integration	Considering how integration should occur between primary and secondary care, what are the most notable findings identified by the analysis in your view?	[Free text]
Quality	Considering the findings of the 5IQ Comparative analysis related to quality metrics, what are the most notable findings in your view?	[Free text]

### Domain 2: How should the Framework be structured?

How do you envisage the Framework being structured? Would you like to have it as a simple list of standards or have several levels of attainment (i.e. Level 1, Level 2, Level 3)? [Free text]

(continued)

**Domain 3: What clinical standards are required?**

This domain seeks your opinions on what specific aspects of care merit having a clinical standard. We invite you to rate the importance or not of having particular standards and invite you to add any comments as free text.

5IQ item	Question	Options
Identification	How important is it to have a standard relating to identification of individuals with <b>fragility fractures</b> ?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to identification of individuals with <b>common risk factors</b> for osteoporosis (e.g. age 70 years or over, early menopause, excessive alcohol intake, family history, height loss, low body mass index/weight, prolonged immobility, smoking)?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to identification of individuals who take <b>medicines associated with bone loss and/or increased fracture risk</b> ?	Extremely important Very important Somewhat important Not so important Not at all important
Investigation	How important is it to have a standard relating to identification of individuals with <b>conditions associated with bone loss and/or increased fracture risk</b> ?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to <b>biochemical investigations</b> of individuals undergoing assessment?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to <b>BMD testing</b> of individuals undergoing assessment?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to use of <b>risk assessment tools</b> for individuals undergoing assessment?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to vertebral fracture assessment for individuals undergoing assessment?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to <b>falls risk assessment</b> for individuals undergoing assessment?	Extremely important Very important Somewhat important Not so important Not at all important
	How important is it to have a standard relating to scenarios when <b>referral to a specialist</b> is required?	Extremely important Very important Somewhat important Not so important Not at all important
Information	How important is it to have a standard relating to what information should be imparted to patients to engage them in their care (e.g. information on calcium intake, sun exposure, the relationship between osteoporosis and fracture risk, exercise and other information)?	Extremely important Very important Somewhat important Not so important Not at all important

(continued)

Intervention	<p>The 5IQ analysis identified a broad range of <b>indications for treatment</b>, as listed below. In your opinion, which of the following indications for treatment should feature in osteoporosis clinical guidelines? Please indicate in priority order (where number 1 is the highest priority). Only provide rankings for those indications which you believe should be included.</p> <p><input type="checkbox"/> Hip fracture</p> <p><input type="checkbox"/> Vertebral fracture</p> <p><input type="checkbox"/> Non-hip, non-vertebral fracture</p> <p><input type="checkbox"/> BMD T-Score <math>\leq -2.5</math> SD</p> <p><input type="checkbox"/> Osteopenia + FRAX® <math>\geq 3\%</math> Hip or <math>\geq 20\%</math> MOF</p> <p><input type="checkbox"/> Osteopenia + RFs or eligible by OSTA or SCORE</p> <p><input type="checkbox"/> Osteopenia + <math>\geq 10</math> years postmenopausal</p> <p><input type="checkbox"/> FRAX® or Garvan <math>\geq 3\%</math> Hip or <math>\geq 20\%</math> MOF</p> <p><input type="checkbox"/> Eligible by OSTA, MORES or SCORE</p> <p><input type="checkbox"/> QCT <math>&lt; 80</math> mg/cm<sup>3</sup></p> <p><input type="checkbox"/> Height loss <math>&gt; 4</math> cm</p> <p><input type="checkbox"/> Androgen deprivation therapy use</p> <p><input type="checkbox"/> Aromatase inhibitor use</p> <p><input type="checkbox"/> Glucocorticoid use</p> <p><input type="checkbox"/> Country-specific thresholds</p>	[Select items and rank according to priority]
	How important is it to have a standard relating to which <b>pharmacological treatments</b> should be recommended for specific patient groups?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>
	How important is it to have a standard relating to which <b>non-pharmacological interventions</b> should be recommended?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>
	How important is it to have a standard relating to description of <b>side effects</b> associated with pharmacological treatments?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>
	How important is it to have a standard relating to <b>monitoring of treatment</b> with pharmacologic agents?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>
	How important is it to have a standard relating to <b>duration of treatment</b> with pharmacologic agents?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>
	How important is it to have a standard relating to <b>treatment adherence</b> with pharmacologic agents?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>
	How important is it to have a standard relating to <b>referral of patients to falls prevention programmes</b> ?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>
Integration	How important is it to have a standard relating to provision of a long-term management plan to the patients and/or primary care provider?	<p>Extremely important</p> <p>Very important</p> <p>Somewhat important</p> <p>Not so important</p> <p>Not at all important</p>

(continued)

Quality	How important is it to have a standard relating to what quality metrics should be in place to assess adherence with guidelines-based care?	Extremely important Very important Somewhat important Not so important Not at all important
<b>General</b>	Do you have any other comments related to the development of the Framework clinical standards?	[Free text]

## Appendix 3 The APCO Framework

Clinical standards	Levels of attainment (where applicable)
1 Men and women who sustain a fragility fracture should be systematically and proactively identified to undergo assessment of bone health and, where appropriate, falls risk.	1. Individuals who sustain hip fractures should be identified. 2: Individuals who sustain hip and/or clinical vertebral fractures should be identified. 3: Individuals who sustain hip, clinical and/or morphometric vertebral, and/or non-hip, non-vertebral major osteoporotic fractures should be identified.
2 Men and women with common risk factors for osteoporosis should be proactively identified to undergo assessment of bone health and, where appropriate, falls risk. A sex-specific age threshold for assessment should be determined for each country or region and should be included in new or revised osteoporosis clinical guidelines.	
3 Men and women who take medicines that are associated with bone loss and/or increased fracture risk should be proactively identified to undergo assessment of bone health and, where appropriate, falls risk. A commentary should be included in new or revised osteoporosis clinical guidelines to highlight commonly used medicines that are associated with bone loss and/or increased fracture risk.	
4 Men and women who have conditions associated with bone loss and/or increased fracture risk should be proactively identified to undergo assessment of bone health. A commentary should be included in new or revised osteoporosis clinical guidelines to highlight common prevalent conditions in the country or region.	
5 The use of country-specific (if available) fracture risk assessment tools (e.g. FRAX®, Garvan, etc.) or osteoporosis screening tools (e.g. OSTA) should be a standard component of investigation of an individual's bone health and prediction of future fracture risk and/or osteoporosis risk.	
6 Assessment for presence of vertebral fracture(s) either by X-ray (or other radiological investigations such as CT or MRI), or by DXA-based VFA should be a standard component of investigation of osteoporosis and prediction of future fracture risk.	1. Individuals presenting with clinical vertebral fractures should undergo assessment for osteoporosis. 2. Individuals with incidentally detected vertebral fractures on X-ray and/or other radiological investigations should be assessed for osteoporosis. 3. Individuals being assessed for osteoporosis should undergo spinal imaging with X-ray or other appropriate radiological modalities, or with DXA-based VFA.
7 A falls risk assessment should be a standard component of investigation of an individual's future fracture risk.	
8 In order to engage individuals in their own care, information should be provided on calcium and vitamin D intake, sun exposure, exercise, and the relationship between osteoporosis and fracture risk.	
9 The decision to treat with osteoporosis-specific therapies and the choice of therapy should be informed as much as possible by country-specific and cost-effective intervention thresholds. Intervention thresholds that can be considered include:	

(continued)

Clinical standards	Levels of attainment (where applicable)
<ul style="list-style-type: none"> <li>• History of fragility fracture</li> <li>• BMD T-Score <math>\leq -2.5</math> S.D.</li> <li>• High fracture risk as assessed by country-specific intervention thresholds.</li> </ul> <p>10 New or revised osteoporosis clinical guidelines should include a commentary on the common side effects of pharmacological treatments that are recommended in the guidelines.</p> <p>11 New or revised osteoporosis clinical guidelines should provide a commentary on monitoring of pharmacological treatments. This could include, e.g. the role of biochemical markers of bone turnover and bone mineral density measurement.</p> <p>12 New or revised osteoporosis clinical guidelines should provide a commentary on the duration of pharmacological treatments that are recommended in the guidelines. This should include a discussion on the appropriate order of sequential treatment with available therapies and the role of 'drug holidays'.</p> <p>13 Assessment of adherence to pharmacological treatments that are recommended in new or revised osteoporosis clinical guidelines should be undertaken on an ongoing basis after initiation of therapy, and appropriate corrective action be taken if treated individuals have become non-adherent.</p> <p>14 New and revised osteoporosis clinical guidelines should provide a commentary on recommended non-pharmacological interventions, such as exercise and nutrition (including dietary calcium intake) and other non-pharmacological interventions (e.g. hip protectors).</p> <p>15 In collaboration with the patient, the treating clinician (hospital specialist and/or primary care provider) should develop a long-term management plan, that, provides recommendations on pharmacological and non-pharmacological interventions to improve bone health and, where appropriate, measures to reduce falls risk.</p> <p>16 New or revised osteoporosis clinical guidelines should provide a commentary on what quality metrics should be in place to assess adherence with guideline-based care.</p>	<ol style="list-style-type: none"> <li>1. Conduct a local 'pathfinder audit' in a hospital or primary care practice to assess adherence to APCO Framework Clinical Standards 1–9, 13 and 15.</li> <li>2. Contribute to a local fracture/osteoporosis registry.</li> <li>3. Contribute to a fracture/osteoporosis registry for your country or region.</li> </ol>

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

## References

1. The Royal Australian College of General Practitioners, Osteoporosis Australia (2017) Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2nd edn. RACGP, East Melbourne
2. Osteoporosis and Bone Mineral Disease Branch of Chinese Medical Association (2017) Guidelines for the diagnosis and treatment of primary osteoporosis (2017). *Chin J Osteo Bone Miner Res* 10:413–444
3. Workgroup of 2018 China Guideline for the Diagnosis and Treatment of Senile Osteoporosis, Osteoporosis Society of China Association of Gerontology and Geriatrics, Ma Y et al (2018) 2018 China guideline for the diagnosis and treatment of senile osteoporosis [in Chinese]. *Chin J Health Manage* 12:484–509
4. Osteoporosis Group Orthopaedic Branch Chinese Medical Association, Liu Q, Cao L et al (2017) Guidelines for the diagnosis and treatment of osteoporotic fractures [in Chinese]. *Chin J Orthop* 37:1–10
5. OSHK Task Group for Formulation of OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, Ip TP, Cheung SK et al (2013) The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. *Hong Kong Med J* 19(Suppl 2):1–40
6. Huang Z, Fang Y, Wu Z et al (2017) 2017 Consensus and guidelines for the prevention and treatment of adult osteoporosis in Taiwan. Taiwanese Osteoporosis Association, Taipei

7. Singh M, Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2020) Clinical practice guidelines on postmenopausal osteoporosis: An executive summary and recommendations - Update 2019. Indian Menopause Society, Hyderabad
8. Bhadada SK (2020) Indian society for bone and mineral research guidelines 2020. Indian Society for Bone and Mineral Research, New Delhi
9. Setyohadi B, Hutagalung EUHU, Frederik Adam JM et al (2012) Summary of the Indonesian guidelines for diagnosis and management of osteoporosis. *JAFES* 27:147
10. Orimo H (2015) Japanese 2015 guidelines for the prevention and treatment of osteoporosis [in Japanese]. Japan Osteoporosis Society, The Japanese Society for Bone and Mineral Research & Japan Osteoporosis Foundation, Tokyo
11. Chan SP, Yeap SS, Lee EGM, Chee W, Hew FL, Lee JK, Lim HH, Damodaran P, Mumtaz M (2015) Clinical guidance on management of osteoporosis, 2nd edn. Malaysian Osteoporosis Society, Academy of Medicine & Ministry of Health, Malaysia, Petaling Jaya
12. Latt TS, Aye TT, Ko K, Myint T, Hliang NN, Thauang M, Chit TT (2012) Myanmar clinical practice guidelines for osteoporosis. *JAFES* 27:151–155
13. Gilchrist N, Reid IR, Sankaran S, Kim D, Drewry A, Toop L, McClure F (2017) Guidance on the diagnosis and management of osteoporosis in New Zealand. *Osteoporosis New Zealand*, Wellington
14. Li-Yu J, Perez EC, Canete A, Bonifacio L, Llamado LQ, Martinez R, Lanzon A, Sison M, Osteoporosis Society of Philippines Foundation Inc, Philippine Orthopedic Association Clinical Practice Guidelines Task Force Committee on Osteoporosis (2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. *Int J Rheum Dis* 14:223–238
15. Chandran M, Ang SB, Au L et al (2018) Appropriate care guide: osteoporosis identification and management in primary care. Ministry of Health, Singapore
16. Yoon HG, Jung HY, Yoon BG (2019) KSBMR physician's guide for osteoporosis [in Korean]. Korean Society for Bone and Mineral Research, Seoul
17. Songpatanasilp T, Sritara C, Kittisomprayoonkul W et al (2016) Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. *Osteoporos Sarcopenia* 2:191–207
18. Vietnam Rheumatology Association (2016) Guidelines for the diagnosis and treatment of osteoporosis [in Vietnamese]. Vietnam Rheumatology Association, Hanoi
19. Bhadada SK (2020) Indian Society for Bone and Mineral Research guidelines 2020. Indian Society for Bone and Mineral Research, New Delhi
20. Setyohadi B, Hutagalung EUHU, Frederik Adam JM et al (2012) Summary of the Indonesian guidelines for diagnosis and management of osteoporosis. *JAFES* 27:147–150
21. Orimo H (2015) [Japanese 2015 guidelines for the prevention and treatment of osteoporosis] [in Japanese]. Japan Osteoporosis Society, The Japanese Society for Bone and Mineral Research & Japan Osteoporosis Foundation, Tokyo
22. Chan SP, Yeap SS, Lee EGM, Chee W, Hew FL, Lee JK, Lim HH, Damodaran P, Mumtaz M (2015) Clinical guidance on management of osteoporosis, 2nd edn. Malaysian Osteoporosis Society, Academy of Medicine & Ministry of Health, Malaysia, Petaling Jaya
23. Latt TS, Aye TT, Ko K, Myint T, Hliang NN, Thauang M, Chit TT (2012) Myanmar clinical practice guidelines for osteoporosis. *JAFES* 27:151–155
24. Gilchrist N, Reid IR, Sankaran S, Kim D, Drewry A, Toop L, McClure F (2017) Guidance on the diagnosis and management of osteoporosis in New Zealand. *Osteoporosis New Zealand*, Wellington
25. Li-Yu J, Perez EC, Canete A, Bonifacio L, Llamado LQ, Martinez R, Lanzon A, Sison M, Osteoporosis Society of Philippines Foundation Inc, Philippine Orthopedic Association Clinical Practice Guidelines Task Force Committee on Osteoporosis (2011) Consensus statements on osteoporosis diagnosis, prevention, and management in the Philippines. *Int J Rheum Dis* 14:223–238
26. Chandran M, Ang SB, Au L et al (2018) Appropriate care guide: osteoporosis identification and management in primary care. Ministry of Health, Singapore
27. Yoon HG, Jung HY, Yoon BG (2019) KSBMR physician's guide for osteoporosis [in Korean]. Korean Society for Bone and Mineral Research, Seoul
28. Songpatanasilp T, Sritara C, Kittisomprayoonkul W, Chaiumnuay S, Nimitphong H, Charatcharoenwithaya N, Pongchaiyakul C, Namwongphrom S, Kitumnuaypong T, Srikam W, Dajpratham P, Kuptniratsaikul V, Jaisamrarn U, Tachatraisak K, Rojanasthien S, Damrongwanich P, Wajanavisit W, Pongprapai S, Ongphiphadhanakul B, Taechakraichana N (2016) Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis. *Osteoporos Sarcopenia* 2:191–207
29. Vietnam Rheumatology Association (2016) Guidelines for the diagnosis and treatment of osteoporosis [in Vietnamese]. Vietnam Rheumatology Association, Hanoi
30. Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A brief history of FRAX. *Arch Osteoporos* 13:118
31. Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, Huang QR, Rajatanavin R, Tsai KS, Park HM, Reginster JY, Osteoporosis Self-Assessment Tool for Asians (OSTA) Research Group (2001) A simple tool to identify asian women at increased risk of osteoporosis. *Osteoporos Int* 12:699–705
32. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. *Osteoporos Int* 19:1431–1444
33. International Osteoporosis Foundation IOF Risk Check. IOF. <https://www.iofbonehealth.org/iof-one-minute-osteoporosis-risk-test>
34. Pongchaiyakul C, Nguyen ND, Pongchaiyakul C, Nguyen TV (2004) Development and validation of a new clinical risk index for prediction of osteoporosis in Thai women. *J Med Assoc Thai* 87:910–916
35. Shepherd AJ, Cass AR, Carlson CA, Ray L (2007) Development and internal validation of the male osteoporosis risk estimation score. *Ann Fam Med* 5:540–546
36. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. *Bmj* 339:b4229
37. Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. *Bmj* 344:e3427
38. Cadarette SM, Jaglal SB, Murray TM (1999) Validation of the simple calculated osteoporosis risk estimation (SCORE) for patient selection for bone densitometry. *Osteoporos Int* 10:85–90
39. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. *Osteoporos Int* 19:437–447
40. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (2013) Capture the Fracture: a best practice framework and global campaign to break the fragility fracture cycle. *Osteoporos Int* 24:2135–2152
41. Kristensen PK, Rock ND, Christensen HC, Pedersen AB (2020) The Danish Multidisciplinary Hip Fracture Registry 13-year

- results from a population-based cohort of hip fracture patients. *Clin Epidemiol* 12:9–21
42. National Quality Registers [Sweden] (2019) National Quality Registry for Hip Fracture Patients and Treatment (RIKSHÖFT). <http://kvalitetsregister.se/englishpages/findaregistry/registerarkivenglish/nationalqualityregistryforhipfracturepatientsandtreatmentrikshoft.2402.html> Accessed Nov 2020
  43. Australian and New Zealand Hip Fracture Registry (2019) Australian and New Zealand Hip Fracture Registry [website]. <http://www.anzhfr.org/> Accessed Nov 2020
  44. Gjertsen JE, Engesaeter LB, Furnes O, Havelin LI, Steindal K, Vinje T, Fevang JM (2008) The Norwegian Hip Fracture Register: experiences after the first 2 years and 15,576 reported operations. *Acta Orthop* 79:583–593
  45. Alarcon T, Ojeda-Thies C, Sáez-López P, Gomez-Campelo P, Navarro-Castellanos L, Otero-Puime A, González-Montalvo JI (2020) Usefulness of a national hip fracture registry to evaluate the profile of patients in whom antiosteoporotic treatment is prescribed following hospital discharge. *Osteoporos Int* 31:1369–1375
  46. Neuburger J, Currie C, Wakeman R, Tsang C, Plant F, De Stavola B, Cromwell DA, van der Meulen J (2015) The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England: an external evaluation using time trends in non-audit data. *Med Care* 53:686–691
  47. Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA (2007) Prior fractures are common in patients with subsequent hip fractures. *Clin Orthop Relat Res* 461:226–230
  48. McLellan AR, Reid DM, Forbes K, Reid R, Campbell C, Gregori A, Raby N, Simpson A (2004) Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland. CEPS: 99/03. NHS Quality Improvement Scotland, Glasgow
  49. Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. *Bone* 35:375–382
  50. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res* 15:721–739
  51. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. *Jama* 301:513–521
  52. Chan DD, Chang LY, Akesson KE et al (2018) Consensus on best practice standards for fracture liaison service in the Asia-Pacific region. *Arch Osteoporos* 13:59
  53. Walters S, Khan T, Ong T, Sahota O (2017) Fracture liaison services: improving outcomes for patients with osteoporosis. *Clin Interv Aging* 12:117–127
  54. Wu CH, Chen CH, Chen PH, Yang JJ, Chang PC, Huang TC, Bagga S, Sharma Y, Lin RM, Chan DC (2018) Identifying characteristics of an effective fracture liaison service: systematic literature review. *Osteoporos Int* 29:1023–1047
  55. Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH, Singh S, Dasari M, Chen JF, Tsai KS (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. *Bone* 111:92–100
  56. Australian and New Zealand Bone and Mineral Society (2016) Secondary fracture prevention program initiative: resource 1 – secondary fracture prevention program resource pack. Australian and New Zealand Bone and Mineral Society, Sydney
  57. Wang O, Hu Y, Gong S, Xue Q, Deng Z, Wang L, Liu H, Tang H, Guo X, Chen J, Jia X, Xu Y, Lan L, Lei C, Dong H, Yuan G, Fu Q, Wei Y, Xia W, Xu L (2015) A survey of outcomes and management of patients post fragility fractures in China. *Osteoporos Int* 26:2631–2640
  58. Tian M, Gong X, Rath S, Wei J, Yan LL, Lamb SE, Lindley RI, Sherrington C, Willett K, Norton R (2016) Management of hip fractures in older people in Beijing: a retrospective audit and comparison with evidence-based guidelines and practice in the UK. *Osteoporos Int* 27:677–681
  59. Chang LY, Tsai KS, Peng JK, Chen CH, Lin GT, Lin CH, Tu ST, Mao IC, Gau YL, Liu HC, Niu CC, Hsieh MH, Chien JT, Hung WC, Yang RS, Wu CH, Chan DC (2018) The development of Taiwan Fracture Liaison Service network. *Osteoporos Sarcopenia* 4:47–52
  60. Leung KS, Yuen WF, Ngai WK, Lam CY, Lau TW, Lee KB, Siu KM, Tang N, Wong SH, Cheung WH (2017) How well are we managing fragility hip fractures? A narrative report on the review with the attempt to setup a Fragility Fracture Registry in Hong Kong. *Hong Kong Med J* 23:264–271
  61. Chandran M, Tan MZ, Cheen M, Tan SB, Leong M, Lau TC (2013) Secondary prevention of osteoporotic fractures—an “OPTIMAL” model of care from Singapore. *Osteoporos Int* 24:2809–2817
  62. Hagino H, Sawaguchi T, Endo N, Ito Y, Nakano T, Watanabe Y (2012) The risk of a second hip fracture in patients after their first hip fracture. *Calcif Tissue Int* 90:14–21
  63. Baba T, Hagino H, Nonomiya H, Ikuta T, Shoda E, Mogami A, Sawaguchi T, Kaneko K (2015) Inadequate management for secondary fracture prevention in patients with distal radius fracture by trauma surgeons. *Osteoporos Int* 26:1959–1963
  64. Iba K, Dohke T, Takada J, Sasaki K, Sonoda T, Hanaka M, Miyano S, Yamashita T (2018) Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years. *J Orthop Sci* 23:127–131
  65. Braatvedt G, Wilkinson S, Scott M, Mitchell P, Harris R (2017) Fragility fractures at Auckland City Hospital: we can do better. *Arch Osteoporos* 12:64
  66. Kim SR, Park YG, Kang SY, Nam KW, Park YG, Ha YC (2014) Undertreatment of osteoporosis following hip fractures in jeju cohort study. *J Bone Metab* 21:263–268
  67. Kim SC, Kim MS, Sanfèlix-Gimeno G et al (2015) Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. *Am J Med* 128:519–526.e511
  68. Yu YM, Lee JY, Lee E (2017) Access to anti-osteoporosis medication after hip fracture in Korean elderly patients. *Maturitas* 103:54–59
  69. Jung Y, Ko Y, Kim HY, Ha YC, Lee YK, Kim TY, Choo DS, Jang S (2019) Gender differences in anti-osteoporosis drug treatment after osteoporotic fractures. *J Bone Miner Metab* 37:134–141
  70. Anghthong C, Rodjanawijitkul S, Samart S, Anghthong W (2013) Prevalence of bone mineral density testing and osteoporosis management following low- and high-energy fractures. *Acta Orthop Traumatol Turc* 47:318–322
  71. Ebeling PR, Chan DC, Lau TC, Lee JK, Songpatanasilp T, Wong SH, Hew FL, Sethi R, Williams M (2020) Secondary prevention of fragility fractures in Asia Pacific: an educational initiative. *Osteoporos Int* 31:805–826
  72. Johnell O, Oden A, Caullin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. *Osteoporos Int* 12:207–214
  73. Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. *Osteoporos Int* 17:1353–1357
  74. Giangregorio LM, Leslie WD (2010) Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. *J Bone Miner Res* 25:1400–1405
  75. Roux C, Briot K (2017) Imminent fracture risk. *Osteoporos Int* 28:1765–1769

76. Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. *Osteoporos Int* 28:775–780
77. Bonafede M, Shi N, Barron R, Li X, Crittenden DB, Chandler D (2016) Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data. *Arch Osteoporos* 11:26
78. Deloumeau A, Moltó A, Roux C, Briot K (2017) Determinants of short term fracture risk in patients with a recent history of low-trauma non-vertebral fracture. *Bone* 105:287–291
79. Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders KM, Sigurdsson G, Siggeirsdóttir K, Fitzpatrick LA, Borgström F, McCloskey EV (2018) Characteristics of recurrent fractures. *Osteoporos Int* 29:1747–1757
80. Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, Cooper C, Rizzoli R, Adib G, al-Daghri N, Campusano C, Chandran M, Dawson-Hughes B, Javaid K, Jiwa F, Johansson H, Lee JK, Liu E, Messina D, Mkinsi O, Pinto D, Prieto-Alhambra D, Saag K, Xia W, Zakraoui L, Reginster JY (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. *Osteoporos Int* 31:1–12
81. Kanis J, Johansson H, Harvey N, Gudnason V, Sigurdsson G, Siggeirsdóttir K, Lorentzon M, Liu E, Vandenput L, McCloskey E (2020) Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. *Osteoporos Int* 31:1817–1828
82. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurlley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB (2020) American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2020 update. *Endocr Pract* 26:1–46
83. Kendler DL, Marin F, Zerbinì CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Mörcke R, López-Romero P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet* 391:230–240
84. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med* 377:1417–1427
85. Ettinger B, San Martin J, Crans G, Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. *J Bone Miner Res* 19:745–751
86. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP, for the Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. *J Clin Endocrinol Metab* 93:3785–3793
87. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey E, EUROFORs Investigators (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab* 93:852–860
88. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. *Lancet* 386:1147–1155
89. Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbinì CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. *N Engl J Med* 375:1532–1543
90. Hiligsmann M, Evers SM, Ben Sedrine W, Kanis JA, Ramaekers B, Reginster JY, Silverman S, Wyers CE, Boonen A (2015) A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. *Pharmacoeconomics* 33:205–224
91. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. *Osteoporos Int* 19:1395–1408
92. Lippuner K, Johansson H, Borgström F, Kanis JA, Rizzoli R (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. *Osteoporos Int* 23:2579–2589
93. McCloskey E, Kanis JA, Johansson H, Harvey N, Odén A, Cooper A, Cooper C, Francis RM, Reid DM, Marsh D, Selby P, Thompson F, Hewitt S, Compston J (2015) FRAX-based assessment and intervention thresholds – an exploration of thresholds in women aged 50 years and older in the UK. *Osteoporos Int* 26:2091–2099
94. Hiligsmann M, Williams SA, Fitzpatrick LA, Silverman SS, Weiss R, Reginster JY (2020) Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: a US payer perspective. *Semin Arthritis Rheum* 50:394–400
95. Chandran M, Ganesan G, Tan KB, Reginster JY, Hiligsmann M (2021) Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women. *Osteoporos Int* 32:133–144. <https://doi.org/10.1007/s00198-00020-05536-00194>
96. Cui L, He T, Jiang Y, Li M, Wang O, Jiajue R, Chi Y, Xu Q, Xing X, Xia W (2020) Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data. *Osteoporos Int* 31:307–316
97. Li N, Zheng B, Liu M, Zhou H, Zhao L, Cai H, Huang J (2019) Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China. *Menopause* 26:906–914
98. Yoshizawa T, Nishino T, Okubo I, Yamazaki M (2018) Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate. *Arch Osteoporos* 13:94
99. Moriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. *Osteoporos Int* 28:1939–1950
100. Karnon J, Shafie AS, Orji N, Usman SK (2016) What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. *Cost Eff Resour Alloc* 14:11

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Affiliations

M. Chandran<sup>1</sup>  · P. J. Mitchell<sup>2</sup>  · T. Amphansap<sup>3</sup>  · S. K. Bhadada<sup>4</sup> · M. Chadha<sup>5</sup> · D.-C. Chan<sup>6</sup> · Y.-S. Chung<sup>7</sup>  · P. Ebeling<sup>8</sup> · N. Gilchrist<sup>9</sup> · A. Habib Khan<sup>10</sup>  · P. Halbout<sup>11</sup> · F. L. Hew<sup>12</sup> · H.-P. T. Lan<sup>13</sup> · T. C. Lau<sup>14</sup> · J. K. Lee<sup>15</sup> · S. Lekamwasam<sup>16</sup> · G. Lyubomirsky<sup>17</sup> · L. B. Mercado-Asis<sup>18</sup> · A. Mithal<sup>19</sup> · T. V. Nguyen<sup>20</sup> · D. Pandey<sup>21</sup> · I. R. Reid<sup>22</sup> · A. Suzuki<sup>23</sup> · T. T. Chit<sup>24</sup> · K. L. Tiu<sup>25</sup> · T. Valleenukul<sup>26</sup> · C. K. Yung<sup>27</sup> · Y. L. Zhao<sup>28</sup> · on behalf of the Asia Pacific Consortium on Osteoporosis (APCO)

- 1 Department of Endocrinology, Osteoporosis and Bone Metabolism Unit, Singapore General Hospital, 20, College Road, Academia, Singapore 169856, Singapore
- 2 Synthesis Medical NZ Limited, Pukekohe, Auckland, New Zealand
- 3 Department of Orthopedics, Police General Hospital, Bangkok, Thailand
- 4 Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
- 5 Department of Endocrinology, Hinduja Hospital and Research Centre, Mumbai, India
- 6 Internal Medicine, National University Hospital Chu-Tung Branch, Chinese Taipei, Taiwan
- 7 Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea
- 8 Department of Medicine in the School of Clinical Sciences, Monash Health, Melbourne, Australia
- 9 Canterbury District Health Board, Christchurch, New Zealand
- 10 Section of Chemical Pathology, Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan
- 11 International Osteoporosis Foundation, Nyon, Switzerland
- 12 Department of Medicine, Subang Jaya Medical Centre, Subang Jaya, Malaysia
- 13 Musculoskeletal and Metabolic Unit, Biomedical Research Center, Pham Ngoc Thach University of Medicine, Bone and Muscle Research Group, Ton Duc Thang University, Ho Chi Minh City, Vietnam
- 14 Division of Rheumatology, Department of Medicine, National University Hospital, Singapore, Singapore
- 15 Department of Orthopedics, Beacon International Specialist Centre, Petaling Jaya, Malaysia
- 16 Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka
- 17 Osteoporosis Australia, Sydney, Australia
- 18 Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines
- 19 Endocrinology, Diabetes Division, Mithal, M. Max Healthcare - Pan-Max, Gurgaon, India
- 20 Genetics and Epidemiology of Osteoporosis Laboratory, Bone Biology Division, Garvan Institute of Medical Research, Sydney, Australia
- 21 Department of Orthopaedics, National Trauma Centre, Kathmandu, Nepal
- 22 Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
- 23 Department of Endocrinology, School of Medicine, Fujita Health University, Toyoake, Japan
- 24 East Yangon General Hospital, Yangon, Myanmar
- 25 Polytrauma and Fragility Fracture team, Department of Orthopaedics and Traumatology, Queen Elizabeth Hospital, Hong Kong, SAR, China
- 26 Department of Orthopedics, Bhumibol Adulyadej Hospital, Bangkok, Thailand
- 27 Department of Endocrinology and Patient Safety Unit, Raja Isteri Pengiran Anak Saleha Hospital, Bandar Seri Begawan, Brunei Darussalam
- 28 Department of Obstetrics and Gynecology, Beijing United Family Hospital, Beijing, China